Compared to Estimates, Halozyme Therapeutics (HALO) Q4 Earnings: A Look at Key Metrics
Halozyme Therapeutics (HALO) reported $230.04 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 26.7%. EPS of $0.82 for the same period compares to $0.48 a year ago.
The reported revenue represents a surprise of -2.22% over the Zacks Consensus Estimate of $235.25 million. With the consensus EPS estimate being $0.82, the company has not delivered EPS surprise.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Halozyme Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenues- Product sales, net: $79.60 million compared to the $77.51 million average estimate based on seven analysts. The reported number represents a change of +30.2% year over year.
Revenues- Royalties: $122.05 million versus the seven-analyst average estimate of $122.61 million. The reported number represents a year-over-year change of +15.2%.
Revenues- Revenues under collaboration agreements: $28.39 million versus the seven-analyst average estimate of $32.12 million. The reported number represents a year-over-year change of +97.8%.
View all Key Company Metrics for Halozyme Therapeutics here>>>
Shares of Halozyme Therapeutics have returned +6.2% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Halozyme Therapeutics, Inc. (HALO) : Free Stock Analysis Report
